Concepedia

Target Populations and Treatment Cost for Bempedoic Acid and PCSK9 Inhibitors: A Simulation Study in a Contemporary CAD Cohort

Christopher Blaum, Fabian J. Brunner, Alina Goßling, Friederike Kröger, Benjamin Bay, Thiess Lorenz, Annika Graef, Tanja Zeller, Renate B. Schnabel, Peter Clemmensen,

Clinical Therapeutics · 2021 · 21 citations · 22 references

DOI

Concepts

References

22

2019 ESC/EAS Guidelines for the management of dyslipidaemias: <i>lipid modification to reduce cardiovascular risk</i>

François Mach, Colin Baigent, Alberico L. Catapano et al. · European Heart Journal · 2019 · 8.9K citations · Full text

, , +17

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

Kausik K. Ray, R. Scott Wright, David Kallend et al. · New England Journal of Medicine · 2020 · 1.6K citations · Full text

, , +17

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol

Kausik K. Ray, Harold Bays, Alberico L. Catapano et al. · New England Journal of Medicine · 2019 · 796 citations · Full text

, , +17

EU-Wi<i>d</i>e Cross-Section<i>a</i>l Obser<i>v</i>at<i>i</i>o<i>n</i>al Study of Lipid-Modifying Therapy Use in Se<i>c</i>ondary and Pr<i>i</i>mary Care: the DA VINCI study

Kausik K. Ray, Bart Molemans, W. Marieke Schoonen et al. · European Journal of Preventive Cardiology · 2020 · 767 citations · Full text

, , +16

Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis

Stephen L. Pinkosky, Roger S. Newton, Emily A. Day et al. · Nature Communications · 2016 · 481 citations · Full text

, , +17